Monkeypox vaccine product: ‘Adequate vaccines are available’ | Monkeypox – science

Monkeypox vaccine product: 'Adequate vaccines are available' |  Monkeypox - science

According to monkeypox vaccine producer Imvanex, no vaccine shortages are expected in the current outbreak. “We believe we can meet global demand without additional investments in our production facilities,” Danish Bavarian-Scandinavian spokesman Rolf Sas Sorensen told the German news agency DPA.

Bavarian Nordic is headquartered in Denmark, where the vaccine is also produced. The company is the only company in the world that has a license for a monkeypox vaccine. Currently, 30 million doses can be produced annually, according to Sorensen.

However, licensing is limited to the United States and Canada, where the vaccine is known as Jynneos. Sorensen says approval in the European Union is currently in the works. In Europe, the vaccine has so far been allowed only for smallpox in humans, which is considered extinct. In Great Britain, the vaccine is used “off-label” or unregistered, ie without corresponding approval.

very safe vaccine

The spokesman refused to reveal the exact quantities of the vaccine that were sold to any country. He stressed that the company is currently receiving inquiries “from many, many countries” and is likely to receive similar requests from all countries affected by the current outbreak.

The impetus for the development of the Scandinavian Bavarian smallpox vaccine came through cooperation with the United States government. After the attack on the World Trade Center in 2001, the government, fearing a smallpox attack, made plans to vaccinate the entire population, says Sorensen. However, the ancient vaccines had significant side effects. “That’s why they came to us to make a better, newer smallpox vaccine.” It is a very safe vaccine that has been tested on the basis of very strong data, the spokesperson said.

See also  Watch the Olympic Games online, TV, and team

Leave a Reply

Your email address will not be published.